Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes
Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, bu...
| Үндсэн зохиолчид: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Journal article |
| Хэл сонгох: | English |
| Хэвлэсэн: |
Cell Press
2017
|
| _version_ | 1826268894152622080 |
|---|---|
| author | Unnikrishnan, A Deshpande, NP Verma, A Kumari, A Richards, LA Knezevic, K Chandrakanthan, V Thoms, JAI Tursky, ML Huang, Y Ali, Z Olivier, J Galbraith, S Kulasekararaj, AG Tobiasson, M Karimi, M Pellagatti, A Wilson, SR Lindeman, R Young, B Ramakrishna, R Arthur, C Stark, R Crispin, P Curnow, J Warburton, P Roncolato, F Boultwood, J Lynch, K Jacobsen, SEW Mufti, GJ Hellstrom-Lindberg, E Wilkins, MR MacKenzie, KL Wong, JWH Campbell, PJ Pimanda, JE |
| author_facet | Unnikrishnan, A Deshpande, NP Verma, A Kumari, A Richards, LA Knezevic, K Chandrakanthan, V Thoms, JAI Tursky, ML Huang, Y Ali, Z Olivier, J Galbraith, S Kulasekararaj, AG Tobiasson, M Karimi, M Pellagatti, A Wilson, SR Lindeman, R Young, B Ramakrishna, R Arthur, C Stark, R Crispin, P Curnow, J Warburton, P Roncolato, F Boultwood, J Lynch, K Jacobsen, SEW Mufti, GJ Hellstrom-Lindberg, E Wilkins, MR MacKenzie, KL Wong, JWH Campbell, PJ Pimanda, JE |
| author_sort | Unnikrishnan, A |
| collection | OXFORD |
| description | Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, but only ∼50% of patients respond. A response only manifests after many months of treatment and is transient. The reasons underlying AZA resistance are unknown, and few alternatives exist for non-responders. Here, we show that AZA responders have more hematopoietic progenitor cells (HPCs) in the cell cycle. Non-responder HPC quiescence is mediated by integrin α5 (ITGA5) signaling and their hematopoietic potential improved by combining AZA with an ITGA5 inhibitor. AZA response is associated with the induction of an inflammatory response in HPCs in vivo. By molecular bar coding and tracking individual clones, we found that, although AZA alters the sub-clonal contribution to different lineages, founder clones are not eliminated and continue to drive hematopoiesis even in complete responders. |
| first_indexed | 2024-03-06T21:16:34Z |
| format | Journal article |
| id | oxford-uuid:3ff95b3b-7a63-40de-a9e5-c7ea6efd67e4 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:16:34Z |
| publishDate | 2017 |
| publisher | Cell Press |
| record_format | dspace |
| spelling | oxford-uuid:3ff95b3b-7a63-40de-a9e5-c7ea6efd67e42022-03-26T14:35:23ZIntegrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3ff95b3b-7a63-40de-a9e5-c7ea6efd67e4EnglishSymplectic Elements at OxfordCell Press2017Unnikrishnan, ADeshpande, NPVerma, AKumari, ARichards, LAKnezevic, KChandrakanthan, VThoms, JAITursky, MLHuang, YAli, ZOlivier, JGalbraith, SKulasekararaj, AGTobiasson, MKarimi, MPellagatti, AWilson, SRLindeman, RYoung, BRamakrishna, RArthur, CStark, RCrispin, PCurnow, JWarburton, PRoncolato, FBoultwood, JLynch, KJacobsen, SEWMufti, GJHellstrom-Lindberg, EWilkins, MRMacKenzie, KLWong, JWHCampbell, PJPimanda, JEMyelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, but only ∼50% of patients respond. A response only manifests after many months of treatment and is transient. The reasons underlying AZA resistance are unknown, and few alternatives exist for non-responders. Here, we show that AZA responders have more hematopoietic progenitor cells (HPCs) in the cell cycle. Non-responder HPC quiescence is mediated by integrin α5 (ITGA5) signaling and their hematopoietic potential improved by combining AZA with an ITGA5 inhibitor. AZA response is associated with the induction of an inflammatory response in HPCs in vivo. By molecular bar coding and tracking individual clones, we found that, although AZA alters the sub-clonal contribution to different lineages, founder clones are not eliminated and continue to drive hematopoiesis even in complete responders. |
| spellingShingle | Unnikrishnan, A Deshpande, NP Verma, A Kumari, A Richards, LA Knezevic, K Chandrakanthan, V Thoms, JAI Tursky, ML Huang, Y Ali, Z Olivier, J Galbraith, S Kulasekararaj, AG Tobiasson, M Karimi, M Pellagatti, A Wilson, SR Lindeman, R Young, B Ramakrishna, R Arthur, C Stark, R Crispin, P Curnow, J Warburton, P Roncolato, F Boultwood, J Lynch, K Jacobsen, SEW Mufti, GJ Hellstrom-Lindberg, E Wilkins, MR MacKenzie, KL Wong, JWH Campbell, PJ Pimanda, JE Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes |
| title | Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes |
| title_full | Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes |
| title_fullStr | Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes |
| title_full_unstemmed | Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes |
| title_short | Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes |
| title_sort | integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes |
| work_keys_str_mv | AT unnikrishnana integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT deshpandenp integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT vermaa integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT kumaria integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT richardsla integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT knezevick integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT chandrakanthanv integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT thomsjai integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT turskyml integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT huangy integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT aliz integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT olivierj integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT galbraiths integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT kulasekararajag integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT tobiassonm integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT karimim integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT pellagattia integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT wilsonsr integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT lindemanr integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT youngb integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT ramakrishnar integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT arthurc integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT starkr integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT crispinp integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT curnowj integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT warburtonp integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT roncolatof integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT boultwoodj integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT lynchk integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT jacobsensew integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT muftigj integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT hellstromlindberge integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT wilkinsmr integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT mackenziekl integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT wongjwh integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT campbellpj integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes AT pimandaje integrativegenomicsidentifiesthemolecularbasisofresistancetoazacitidinetherapyinmyelodysplasticsyndromes |